<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Halozyme-Therapeutics-Inc-US40637H1095">Halozyme Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 news-box__source-badge">
          <img class="news-box__source-logo" alt="StocksGuide" src="https://stocksguide.com/assets/logos/stocks_guide-94bb1add.svg" />
        </div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a data-turbo-frame="_top" href="https://stocksguide.com/en/stock/Halozyme-Therapeutics-Inc-US40637H1095#earnings-events-section">Halozyme Therapeutics, Inc. Q2 2026 Earnings Call Transcript, Presentation and Audio available</a>
    </div>

      <a data-controller="earnings-news-cta" data-earnings-news-cta-event-id-value="5440738" data-action="click-&gt;earnings-news-cta#open" data-turbo-frame="_top" class="btn btn-outline-primary btn--small border-0 mt-0 px-2" href="https://stocksguide.com/en/stock/Halozyme-Therapeutics-Inc-US40637H1095?earnings_event_id=5440738">
        Show summary
        <i class="fa fa-arrow-right fa-fw"></i>
</a>  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
      <a data-turbo-frame="_top" href="https://stocksguide.com/en/stock/Halozyme-Therapeutics-Inc-US40637H1095#earnings-events-section">
        <div class="news-box__logo-frame mb-3 mb-md-0">
          <img class="news-box__logo" alt="Halozyme Therapeutics, Inc." src="https://stocksguide.com/rails/active_storage/blobs/proxy/eyJfcmFpbHMiOnsiZGF0YSI6MTc0ODgsInB1ciI6ImJsb2JfaWQifX0=--bfefd554dc9fb169713cd4c3642509b5b71e304e/Halozyme-Therapeutics-Inc-US40637H1095.png" />
          <span class="news-box__logo-label">Earnings Call Transcript</span>
        </div>
</a>  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Halozyme-Therapeutics-Inc-US40637H1095">Halozyme Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/halozyme-reports-record-second-quarter-2026-results-beats-estimates-and-raises-full-year-2026-financial-guidance-302845332.html">HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE</a>
    </div>

      <div class="me-0 me-md-5">
        Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 2026 Financial Guidance Ranges: Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37% Royalty Revenue of $1.220 - $1.245 billion, YOY Growth of 41% - 43% Adjusted EBITDA of $1.225 - $1.280 billion, YOY Growth of 86% - 95% 1 Non-GAAP Diluted EPS of $8.65 - $9.00, YOY Growth of 108...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Halozyme-Therapeutics-Inc-US40637H1095">Halozyme Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investors Business Daily</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investors.com/research/medical-technology-halozyme-stock-halo-2/">This Medical Technology Stock Claws Back To A Buy Zone</a>
    </div>

      <div class="me-0 me-md-5">
        This medical technology name has a patented method of drug delivery. Halozyme stock recently hit a record high with earnings due out soon.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Halozyme-Therapeutics-Inc-US40637H1095">Halozyme Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/halozyme-announces-global-collaboration-and-license-agreement-with-incyte-to-support-the-development-of-subcutaneous-formulations-of-inca033989-using-its-enhanze-technology-302829283.html">Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology</a>
    </div>

      <div class="me-0 me-md-5">
        Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets SAN DIEGO, July 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (&quot;Halozyme&quot; or the &quot;Company&quot;) today announced that it has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Halozyme-Therapeutics-Inc-US40637H1095">Halozyme Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/halozyme-appoints-david-ramsay-as-president-drug-delivery-302815025.html">Halozyme Appoints David Ramsay as President Drug Delivery</a>
    </div>

      <div class="me-0 me-md-5">
        SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (&quot;Halozyme&quot; or the &quot;Company&quot;) today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026. In this newly created role, Mr.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Halozyme-Therapeutics-Inc-US40637H1095">Halozyme Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Market Watch</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.marketwatch.com/story/20-growth-stocks-priced-as-value-stocks-c0f72ad4">20 growth stocks priced as value stocks</a>
    </div>

      <div class="me-0 me-md-5">
        A broad screen of U.S. stocks yields a list of companies trading at low valuations to expected earnings, with high projected revenue growth rates through 2028. The list of 20 stocks includes eight financial services companies, five healthcare names and four in the information technology sector.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Halozyme-Therapeutics-Inc-US40637H1095">Halozyme Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/halozyme-confirms-it-projects-zero-to-minimal-impact-to-royalty-revenue-through-at-least-2035-based-on-newly-released-draft-medicare-drug-price-negotiation-program-proposed-rule-for-ipay-2029-302799891.html">Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029</a>
    </div>

      <div class="me-0 me-md-5">
        SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (&quot;Halozyme&quot; or the &quot;Company&quot;) today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the proposed rule for the Medicare Drug Price Negotiation Program (&quot;Program&quot;) issued by the U.S. Centers for Medicare &amp; Medicaid Services (&quot;CMS&quot;) on June 12, 2026. &quot;Based on our ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Halozyme-Therapeutics-Inc-US40637H1095">Halozyme Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">MarketBeat</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.marketbeat.com/instant-alerts/halozyme-therapeutics-q1-earnings-call-highlights-2026-05-11/?utm_source=snapi">Halozyme Therapeutics Q1 Earnings Call Highlights</a>
    </div>

      <div class="me-0 me-md-5">
        Halozyme Therapeutics NASDAQ: HALO reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Halozyme-Therapeutics-Inc-US40637H1095/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>